KRYS - Krystal Biotech, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

Krystal Biotech, Inc.

2100 Wharton Street
Suite 701
Pittsburgh, PA 15203
United States

Full Time Employees37

Key Executives

NameTitlePayExercisedYear Born
Mr. Krish S. KrishnanChairman, Pres & CEO704.99kN/A1965
Ms. Suma M. KrishnanFounder, COO & Director495.44kN/A1965
Mr. Antony A. RileyChief Financial Officer124.27kN/A1967
Ms. Gloria LinAccounting Mang.N/AN/AN/A
Ms. Katherine TuminelloHR & Office Mang.N/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Krystal Biotech, Inc., a gene therapy company, develops and commercializes pharmaceutical products for patients suffering from dermatological diseases in the United States. The company's lead product candidate is KB103, which is in Phase II of a Phase I/II clinical study to treat dystrophic epidermolysis bullosa, a genetic disease. It is also involved in developing KB105 that is in preclinical studies for treating patients with deficient autosomal recessive congenital ichthyosis. The company was formerly known as Krystal Biotech, LLC and changed its name to Krystal Biotech, Inc. in March 2017. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.

Corporate Governance

Krystal Biotech, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.